menu
    • menu
    [{"orgOrder":0,"company":"HK inno.N","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N \/ Not Applicable"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Tegoprazan","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"HK inno.N \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"HK inno.N","sponsor":"ILIAS Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Exosome-loaded Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HK inno.N \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"HK inno.N \/ HK inno.N"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Gicell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HK inno.N \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"HK inno.N \/ HK inno.N"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"HK inno.N","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"HK inno.N \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ HK inno.N"}]

    Find Clinical Drug Pipeline Developments & Deals by HK inno.N

    Menu

    HK inno.N

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ecnoglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Recipient : Sciwind Biosciences

                            Deal Size : $56.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sciwind Biosciences & HK inno.N ink $56 M Deal to Treat Metabolic Diseases in Korea

                            Details : HK inno.N gains exclusive rights for XW003 (ecnoglutide), a GLP-1 analog, in Korea; Sciwind retains rights in other global markets.

                            Brand Name : XW003

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : Ecnoglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Recipient : Sciwind Biosciences

                            Deal Size : $56.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Gicell

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GICELL Announces Research Collaboration with HK inno.N For Next-Generation CAR-NK Therapy

                            Details : As part of this agreement, the companies may open up a discussion on further developments, including clinical development and commercialization, if they succeed in discovering CAR-NK cell product candidates and producing non-clinical samples.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 29, 2022

                            Lead Product(s) : Allogeneic CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Gicell

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exosome-loaded Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : ILIAS Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ILIAS Biologics Signed An MOU with HK inno.N For Joint Research

                            Details : With the MOU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 27, 2022

                            Lead Product(s) : Exosome-loaded Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : ILIAS Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Dr. Reddy’s Laboratories to Commercialise Novel Molecule Tegoprazan in India

                            Details : Under this partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan (CJ-12420), while Dr. Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territori...

                            Brand Name : CJ-12420

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 11, 2022

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            HK inno.N

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hk Inno.N Publishes P3 Trial Results of Drug on Gastric Ulcers

                            Details : In the study, cohorts with 50 and 100 milligrams of K-CAB tablets showed superior therapeutic effect and safety in treating gastric ulcers than the group administered with 30 milligrams of Lansoprazole.

                            Brand Name : K-CAB

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : Tegoprazan

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth